secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0000950170-23-071093
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics amends bylaws to align with universal proxy rules and update stockholder meeting procedures
--------------------------------------------------------------------------------

- Board approved amended bylaws effective Dec 14, 2023, addressing SEC universal proxy Rule 14a-19.
- New rules require additional disclosures from stockholders nominating directors or proposing business.
- Stockholders soliciting proxies must use a non-white proxy card; obsolete provisions deleted.
- Changes are procedural and governance-related; no financial impact disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/0000950170-23-071093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/lyra-20231214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-071093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer